Is adjuvant immunotherapy necessary in non-small cell lung cancer?

David Carbone, MD, PhD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, comments on the role of adjuvant immunotherapy in treating non-small cell lung cancer (NSCLC). Results from the CheckMate 816 (NCT02998528) and AEGEAN (NCT03800134) trials have demonstrated modest survival benefit in patients who receive neoadjuvant and adjuvant chemoimmunotherapy. However, since findings from the LCMC3 study (NCT02927301) of neoadjuvant atezolizumab provide similar results, further research is required to assess the role of adjuvant immunotherapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.